Definium Therapeutics develops psychedelic-based therapeutics for psychiatric and neurological disorders. The company focuses on LSD- and MDMA-derived candidates to address conditions such as Generalized Anxiety Disorder, Major Depressive Disorder, and Autism Spectrum Disorder. Lead asset DT120 is an orally disintegrating tablet formulation of Lysergide (LSD) D-tartrate in Phase 3 trials for anxiety and depression. DT402 is the R-enantiomer of MDMA being advanced for core symptoms of Autism Spectrum Disorder. The organization conducts clinical trials to evaluate safety and efficacy and aims to create new treatment options for people with limited response to current therapies.